Last reviewed · How we verify

NCT06033716

Development and Relationship Between Resilience and Anxiety and Depression in Elderly Gastric Cancer Survivors

Completed Last updated 13 September 2023
What this trial tests

trial testing Measurement correlation variable in Resilience in 412 participants. Completed in 31 October 2022.

Timeline
1 March 2021
Primary endpoint
31 October 2022
31 October 2022

Quick facts

Lead sponsorNanjing Medical University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment412
Start date1 March 2021
Primary completion31 October 2022
Estimated completion31 October 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Nanjing Medical University

Who can join

60 and older, any sex, with Resilience or Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will explore the dynamic interaction between mental resilience, anxiety and depression in elderly patients with gastric cancer 1 year after surgery, in order to better understand the role of these two factors in patients' mental health, and provide accurate insights for clinical practice and targeted psychological support strategies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Resilience

Currently open trials in the same condition.

Other Nanjing Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06033716.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing